thyme feedback initi
initi coverag oct outperform rate receiv
feedback sever investor agre view
sell-off ahead novemb fda ad present attract buy
opportun stock ytd vs nbi other
concern binari event risk either case seem consensu
among bull bear alik primari driver valuat
ad iv brexanolon provid import read across whatev
outcom remain bullish ad believ unlock signific
sharehold valu favor pleas see detail
meet psychopharmacolog drug drug safety/risk
manag committeess discuss brexanolon nda partum
depress investor question purpos ad
believ standard procedur drug novel mechan new
indic howev caution brief document may view
sinc iv brexanolon first sever rapidli act anti-depress
potenti seek fda approv believ unmet need clear drive forc
encourag commentari yesterday regard esketamin
fda breakthrough therapi design btd iv brexanolon plu
ema prime emphas signific unmet need
import regul
believ favor ad iv brexanolon would provid posit
setup ahead top-lin result time
uncertain studi still enrol accord ct gov believ
top line might come decemb iv brexanolon pdufa could
provid addit support approv top line
investor worri risk high placebo respons
studi read across brexanolon clearli
separ placebo primari efficaci endpoint part due
rapid onset note similar iv brexanolon
molecular structur exhibit mechan action alloster gaba
hypothet sotp analysi show iv brexanolon contribut
per share valuat exhibit expect read across
fda ad leverag contribut
mdd key driver
therapeut clinical-stag
develop novel medicin
transform live patient life-
analyst certif import disclosur see disclosur
brexanalon receiv fda approv decemb
launch
progress mdd
outperform-r base view
compani leader disord especi
depress two major drug develop brexanolon
postpartum depress
major depress disord mdd compound
alloster modul gaba receptor offer new
mechan action treat depress could address
initi trial pd
adcomm brexanolon
receipt ema scientif advic brexanolon
data
initi mdd trial
data competitor top-line data
brexanolon approv eu
open-label lte trial requir file
brexanolon fail get approv us
schedul sever
valu use dcf analysi assum wacc residu growth rate due loss ip
protect addit pipelin asset unrisk-adjust ww sale estim asset brexanolon risk-
adjust risk-adjust model probabl success brexanolon
mdd
key downsid risk price target clinic develop risk regulatori risk brexanolon addit
risk come lower expect peak sale due higher anticip competit failur gain support
medic commun healthcar prescrib third-parti payor risk relat legal challeng patent protect
exhibit oral daili formul brexanolon
exhibit hypothet sotp valuat use pt calcul driven
johnson johnson nyse cover
